Bayan GLP-1, menene na gaba don asarar nauyi?

GLP-1 agonist Wegovy ya sake ƙarfafa farautar magungunan kiba. Zaɓuɓɓuka - jere daga mahaɗan ɗanɗano mai ɗaci zuwa masu ƙarfafa tsoka da ƙwayoyin cuta - sun riga sun kasance a cikin asibitin.

Semaglutide shine glucagon-kamar peptide-1 (GLP-1) agonist mai karɓa wanda ake amfani dashi don kula da manya masu ciwon sukari na 2. Yana taimakawa wajen sarrafa matakan sukari na jini ta hanyar haɓaka sakin insulin, rage sakin glucagon, da rage zubar da ciki. Bugu da ƙari, ƙananan allurai na semaglutide kwanan nan an haɓaka su don maganin kiba. Amfani da semaglutide yana buƙatar takardar sayan magani da jagorar likita.

Ƙarin ya shahara sosai a kasuwa cewa mutane da yawa sun gamsu da fa'idodin asarar nauyi wanda ɗan kasuwa biliyoyin Elon Musk ya yi tweet a cikin Oktoba 2022 cewa ya yi amfani da Semaglutide don sauyin asararsa. A ranar 1 ga Oktoba, wani fanni ya buga hotonsa kuma ya tambaye shi menene "asirinsa" don rage kiba. "Azumi," Musk ya amsa, kafin ya kara da cewa: "Kuma Wegovy."

Musamman, Semaglutide na iya samun asarar nauyi ta hanyoyi masu zuwa:

Ciwon abinci: Semaglutide na iya yin aiki ta hanyar tsarin juyayi na tsakiya don hana ci abinci da rage yawan abincin da aka ci.

Haɓaka ƙona kitse: Semiglutide na iya ƙara raguwa da amfani da mai, inganta ƙona kitse, don haka rage tarin kitse.

Daidaita matakan sukari na jini: Semaglutide na iya daidaita matakan sukari na jini kuma ya hana sukarin jini daga yin sama ko ƙasa sosai, don haka rage haɓakar kitse da tarawa.